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Serum protein electrophoresis (SPE), urine protein electrophoresis 
(UPE), immunofixation electrophoresis (IFE) and serum-free light- 
chain (SFLC) analysis are important tests used to diagnose and 
monitor monoclonal gammopathy in B-cell disorders such as multi-
ple myeloma and monoclonal gammopathy of unknown signi ficance 
(MGUS).[1,2]
An audit of SPE tests in a UK hospital servicing a population 
of 759 000 people found that 10 557 SPE tests were conducted in 
2011. A sub-study (n=145) of appropriateness of SPE test requests 
com pared each case history with set audit standards and found that 
26% of requests for SPE tests were inappropriate, with the primary 
care clinical discipline being the largest source of inappropriate 
requests. Most of the appropriate SPE test requests were from clinical 
haematology, renal medicine, rheumatology and geriatric clinical 
disciplines.[3]
A cross-sectional study of inpatient SPE and UPE tests in a tertiary 
hospital in New South Wales, Australia, servicing a population of 
over 1 million, found that 29 607 SPE and 14 374 UPE tests were 
performed over a 5-year period. The mean age of the patients tested 
was 60 years (standard deviation (SD) 19), with 61% females. Results 
were positive for paraprotein in 6.7% of SPE and 0.3% of UPE tests.[4]
A Scottish study investigating the utility of SPE as a screening test 
specifically for renal outpatients over a 2-year period (N=2 544 new 
patients) reported 1 608 tests performed. Approximately 2.5% of 
patients had abnormal SPEP results, of whom 2.5% had MGUS and 
only one developed multiple myeloma on subsequent follow-up.[5]
Studies on the prevalence of electrophoresis testing in a South 
African (SA) pathology laboratory setting are limited. A recent 
retrospective audit at Inkosi Albert Luthuli Central Hospital 
(IALCH), Durban (a quaternary public sector hospital servicing a 
population of 10 million people in KwaZulu-Natal (KZN) Province), 
documented 1 260 SPE tests and 304 IFE tests performed between 
February 2011 and July 2011. The positive test yield from IFE testing 
for the presence of a paraprotein was 46.5%, revealing the need for 
IFE testing following identification of a suspicious SPE pattern.[6] 
A retrospective analysis of medical aid claims for the utilisation 
of a range of pathology procedures from six private sector pathology 
laboratories across SA between 2003 and 2005 showed an increase in 
the number of SPE tests performed across increasing age groups in all 
laboratories investigated. The frequency of SPE testing varied between 
the laboratories, ranging between 8.7% and 55% of all tests requested 
and indicating inappropriate test utilisation in some cases.[7]
Globally, healthcare systems are under pressure to reduce costs 
while continuing to provide quality services. Laboratory medicine 
has been targeted as a potential source of savings, with the 
implementation of principles of demand management and the 
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efficient use of laboratory tests used as a means of cost reduction and 
viewed as a critical function of laboratory managers.[8]
Objectives
To evaluate the prevalence, testing pattern and yield of electro-
phoresis tests performed over a 5-year period in a tertiary academic 
laboratory in SA, and relate these findings to bone marrow biopsy 
findings in a few selected cases.
Methods
Study design
The study was a retrospective audit using data from the Tygerberg 
Academic Hospital (TAH) National Health Laboratory Service 
(NHLS) hospital information system database from 1 July 2010 to 
30 June 2015. TAH is a 1 380-bed tertiary referral academic hospital 
affiliated to Stellenbosch University, and services approximately 
half of the population of the Western Cape Province of SA (total 
population ~6.2 million).[9] The NHLS chemical pathology laboratory 
processes ~100 000 chemistry test requests per month for TAH and 
other public sector hospitals and clinics in the region.
Inclusion criteria were all SPE, UPE and IFE tests conducted on 
new and follow-up adult patients (aged ≥18 years) presenting to 
TAH. SPE, UPE and IFE tests conducted on non-TAH referrals and 
patients aged <18 years were excluded.
A subgroup analysis of all patients with negative serum (SIFE) 
and/or urine immunofixation (UIFE) tests who had concurrent 
bone marrow biopsies close to the time of IFE testing was also 
performed to determine the proportion of cases in which myeloma 
presented in the bone marrow but SIFE and/or UIFE were negative. 
The bone marrow reports of these patients were assessed for the 
percentage of plasma cells present, plasma cell tumour burden and 
light-chain restriction according to international diagnostic criteria 
for myeloma.[1] A negative IFE result was defined as absence of an 
immunoglobulin monoclonal band with absent kappa or lambda 
light-chain restriction.
Ethical considerations
To ensure patient confidentiality, all personal identifying information 
on patients was removed, with only laboratory sample numbers 
used to label the data. Information pertaining to patient samples 
was restricted to members of the research team. The study was 
approved by the Stellenbosch University Health Research Ethics 
Committee (ref. no. N16/01/002) and was in accordance with the 
2013 Declaration of Helsinki.
Laboratory methods
The SPE, UPE and IFE tests were performed on the Sebia Hydrasys 
2 (Sebia, USA) semiautomated electrophoresis system using agarose 
gels. Our laboratory is accredited by the South African National 
Accreditation System and subscribes to internal and external 
proficiency testing schemes, namely Biorad and the Royal College of 
Pathologists of Australia.
The bone marrow biopsy procedures and reporting were per-
formed in the Department of Haematopathology at TAH in accor-
dance with International Council for Standardisation in Haema-
tology guidelines.[10]
Data analysis
Data were analysed using descriptive statistical techniques using 
Micro soft Excel version 14 (USA) and SPSS version 20 (USA) stati-
stical software. Follow-up tests on the same patient were removed. 
Results were summarised as the prevalence of testing, source of test 
requests and test yield by test, year, gender and age. Bone marrow 
biopsy findings (plasma cell percentage, plasma cell tumour burden, 
light-chain restriction) in patients with negative SPE and/or UPE 
tests were tabulated.
Results
Prevalence of testing
A total of 5 086 SPE tests were performed on 2 834 individual patients 
(44.3% of tests were follow-up tests). Of these 2 834 patients, 391 
(13.8%) had SIFE tests. A total of 1 299 UPE tests were performed on 
996 individual patients (23.3% of tests were follow-up tests). Of these 
996 patients, 334 (33.6%) had UIFE tests (Table 1).
The number of SIFE tests performed increased steadily from 60 in 
2010 to 118 in 2015, and the number of UIFE tests rose from 57 in 
2010 to 89 in 2015 (Fig. 1).
The mean age of patients undergoing SIFE tests was 59 years 
(SD 14.2), while that of patients undergoing UIFE tests was 60 years 
(SD 15). The female-to-male ratio was 1.1:1 for both SIFE and UIFE.
Sources of test requests
The main sources of requests for SIFE tests were the haematology 
oncology outpatient (19.8%), orthopaedic inpatient (15.8%), gen-
eral medical inpatient (16.3%), general medical outpatient (15.0%), 
medical casualty (10.8%), neurology inpatient (7.9%), haematology 
inpatient (5.3%) and orthopaedic outpatient (4.1%) departments. 
The main sources of requests for UIFE tests were the general medi-
cal inpatient (24.1%), orthopaedic inpatient (18.2%), haematology 
oncol ogy outpatient (11.6%), general medical outpatient (11.0%), 
haematology inpatient (7.4%), medical casualty (7.1%), neurology 
inpatient (5.4%) and orthopaedic outpatient (2.4%) departments.
Test yield
For SIFE testing, 66.2% of test results were positive for the presence 
of an immunoglobulin monoclonal band with kappa or lambda 
light-chain restriction (Table 2). The specialties with the highest 
positive SIFE test yield were haematology (inpatient 75.0% and 
Table 1. Electrophoresis tests, 2010 - 2015
Test Total tests, N
Tests excluding 
follow-up 
tests, n 
Follow-up 
tests, %
SPE 5 086 2 834 44.3
UPE 1 299 996 23.3
SIFE 403 391 3.0
UIFE 337 334 0.9
Fig. 1. Numbers of SIFE and UIFE tests, 2010 - 2015.
Fig. 1. Numbers of SIFE and UIFE tests, 2010 - 2015. 
 
 
140
120
100
80
60
40
20
0
Te
st
s, 
n
2010/11   2011/12 2012/13 2013/14
Year
2014/15
SIFE UIFE
272       March 2017, Vol. 107, No. 3
RESEARCH
outpatient 85.8%), orthopaedics (outpatient) (80.6%) and medical 
casualty (68.2%) (Table 3).
In contrast, for UIFE testing 46.7% of results were positive for the 
presence of an immunoglobulin monoclonal band with kappa or 
lambda light-chain restriction (Table 2). The haematology outpatient 
department had the highest positive yield (89.7%), while the other 
main specialties requesting UIFE tests had yields ≤50% (Table 3).
Negative SIFE and/or UIFE tests and bone marrow 
biopsy findings
Of the 403 patients with SIFE tests performed during the 5-year 
study period, 126 (31.3%) had negative results. Of these patients, 
20 (15.9%) underwent bone marrow biopsies within 6 months of 
SIFE testing. Eight of these patients (40.0%) showed evidence of 
bone marrow involvement by plasma cells and light-chain restriction 
on immunohistochemical staining, in keeping with a diagnosis of 
myeloma[1] (Table 4).
Of the 334 patients with UIFE tests performed during the 5-year 
study period, 174 (52.1%) had negative results. Of these patients, 10 
(5.7%) had subsequent bone marrow biopsies, none of which showed 
findings in keeping with the diagnosis of myeloma.[1]
Discussion
In this study, we performed a 5-year retrospective audit of the 
prevalence and source of requests for SPE and UPE tests in a tertiary 
laboratory. We also determined the IFE test yield of these requests 
Table 2. Yield for all SIFE and UIFE tests, 2010 - 2015
Test Positive results, n (%)* Negative results, n (%)†
Oligoclonal/polyclonal  
test results, n (%) Total tests, N
SIFE  267 (66.2)  126 (31.3) 10 (2.5) 403
UIFE  156 (46.7)  174 (52.1) 4 (1.2) 334
*Positive results include the presence of an immunoglobulin monoclonal band with kappa or lambda light-chain restriction or the presence of free kappa and/or lambda light chains.
†Negative results include the absence of an immunoglobulin monoclonal band and absence of kappa or lambda light-chain restriction.
Table 3. Positive yield for all SIFE and UIFE tests by specialty, 2010 - 2015
Specialty
Positive SIFE results, 
n (%)
SIFE test positive yield, 
%
Positive UIFE results, 
n (%)
UIFE test positive yield,  
%
Haematology inpatient 15 (5.6) 75.0 10 (6.4) 40.4
Haematology outpatient 67 (25.1) 85.8 35 (22.4) 89.7
Orthopaedics inpatient 34 (13) 54.8 18 (11.5) 22.2
Orthopaedics outpatient 13 (5.0) 80.6 2 (1.3) 24.8
General medical inpatient 38 (14.2) 60.3 33 (21.1) 40.7
General medical outpatient 28 (10.5) 65.1 16 (10.3) 43.2
Medical casualty 28 (10.5) 68.2 12 (7.7) 50.2
Neurology inpatient 13 (5.0) 41.9 7 (4.5) 38.8
Cardiothoracic surgery 2 (0.7) 66.6 6 (3.9) 85.7
Other specialties 29 (10.9) - 17 (10.9) -
Total 267 (100) - 156 (100) -
Table 4. Negative SIFE tests and corresponding bone marrow biopsy findings in keeping with the diagnosis of myeloma,  
2011 - 2015
Bone marrow findings
Patient no.
Plasma cells in bone marrow 
aspirate, %*
Plasma cells in bone marrow 
trephine biopsy (CD138+), %†
Light-chain restriction (kappa and  
lambda immunohistochemistry)*
1 7 15 - 20 Lambda
2 4 15 - 20 Kappa
3 30 Clear aggregates‡ Lambda
4 16 30 Lambda
5 Unable to report‡ 95 Not tested
6 15 80 Lambda
7 4 >20 Lambda
8 14 20 - 30 Lambda
*Confirmed by CD138+ and kappa/lambda light-chain restriction on immunohistochemical staining.
†Plasma cell tumour burden is assessed as the percentage of the cells of interest in relation to all cells present in the bone marrow trephine biopsy only.
‡Poor sample quality, therefore not able to quantify cells accurately.
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and compared the negative SIFE and UIFE tests with bone marrow 
biopsy findings in selected patients from 2010 to 2015 (60 months).
We found that 44.3% of SPE tests and 23.3% of UPE tests were follow-
up tests, with an increasing trend in SIFE and UIFE tests performed from 
2010 to 2015. This increase could be explained by greater awareness of 
electrophoresis testing on the part of doctors, an increasing burden of 
disease, increased requesting for patients with HIV infection, and an 
increasingly ageing population in the Western Cape.[9]
The negative test yields for SIFE and UIFE were 31.3% and 52.1%, 
respectively. Of the patients with a negative SIFE test who had a bone 
marrow biopsy, 40.0% had bone marrow biopsy features in keeping 
with the diagnosis of myeloma. No patient with a negative UIFE test 
who had a bone marrow biopsy had features in keeping with the 
diagnosis of myeloma.
A previous audit at IALCH found that 1 260 SPE tests and 304 
SIFE tests were performed over a 6-month period (February 2011 - 
July 2011).[6] Our audit found that 498 SPE and 36 SIFE tests were 
performed at TAH over the same time period. On average, 509 SPE 
and 40 SIFE tests were done every 6 months at TAH between 
2010 and 2015. The relatively smaller number of tests at TAH 
could be explained by IALCH’s being the only centre performing 
electrophoresis for KZN, compared with two centres in the Western 
Cape (TAH and Groote Schuur Hospital). In addition, there is no 
gatekeeping function for IFE testing at IALCH, so it may be ordered 
for inappropriate indications. Our study also excluded samples from 
referral hospitals and clinics from the analysis. The positive test 
yield for SIFE in our laboratory was higher than at IALCH (66.2% v. 
46.5%).[6] Current practice in our laboratory includes a pathologist 
gatekeeping function for SIFE and UIFE testing based on suspicious 
SPE and UPE results, respectively. In comparison, the study by 
Thakkinstian et al.[4] showed positive results for paraprotein in 6.7% 
of SPE and 0.3% of UPE tests, while Doyle et al.[5] had positive SPE 
findings in 2.5% of renal outpatients in their hospital.
Our laboratory performed fewer SPE tests in relation to the 
population served compared with centres in more developed 
countries.[3-5] For example, 10 557 SPE tests were performed in a UK 
hospital for a population of 759 000 in 2011,[3] compared with 1 013 
tests at TAH for a population of ~3.6 million in the same year.
Comparing our study with the multi-laboratory study (2003 - 2005) 
by Pretorius,[7] which showed an increasing trend in test requests with 
increasing age groups up to >70 years, we found a similar trend in 
our study up to ~63 years of age for all tests. SPE tests constituted the 
majority (71.3%) of all electrophoresis tests performed, suggesting 
that SPE test requesting patterns have not changed in the past decade, 
with the exception of fewer tests now being performed in the age 
group >70 years compared with 60 - 69-year-olds.
The patients in our study with negative SIFE and UIPE tests 
probably had bone marrow biopsies performed owing to strong 
clinical suspicion or because they had symptoms of myeloma despite 
negative IFE results. Our finding that only 15.9% of patients with 
negative SIFE tests had bone marrow biopsies, of whom 40.0% (6.3% 
of all negative SIFE tests) had positive bone marrow involvement 
of plasma cells, highlights the value of clinical findings and other 
test results in the initial diagnosis of myeloma. This pattern is also 
suggestive of non-secretory myeloma, where the presence of serum 
or urine monoclonal protein is not mandatory for diagnosis of 
myeloma and further diagnostic confirmation with SFLC analysis 
is necessary.[1] Bone marrow biopsy in combination with SIFE and 
UIFE is also used to monitor response to therapy for myeloma.[11]
Other diagnostic modalities for improving the accuracy of 
diagnosis of plasma cell disorders include SPE testing combined 
with SFLC testing as first-line investigations, which have shown 
100% sensitivity and 97% specificity for the detection of plasma cell 
disorders,[12] and the use of a clinical decision rule for SPE and UPE 
testing using age (≥60 years), gender, haemoglobin concentration 
(<12.1 g/dL), globulin level (>41 g/L) and estimated glomerular 
filtration rate (<60 mL/min/1.73 m2), which has been shown to have 
an area under the curve of 0.81 after validation.[4]
Study limitations and strengths
This study had several limitations. Unfortunately the time of presen-
tation was not always available, so we were not able to calculate the 
time taken to reach a diagnosis. A further potential limitation was 
the subjectivity associated with the interpretation of electrophoresis 
test results and the fact that the tests were interpreted by numerous 
pathologists. Test request information and background clinical infor-
mation were often incomplete, so the appropriateness of testing by 
clinical discipline could not be assessed. However, strengths were that 
this audit was performed over a long time period of 5 years and only 
one method was used for SPE and UPE testing.
Conclusion
This audit provides baseline data on the prevalence of electrophoresis 
testing, the source of test requests and test yield in our laboratory, 
providing useful data for future studies involving plasma cell 
disorders. The practice of gatekeeping of IFE testing at our hospital 
has shown benefits, with relatively few SIFE tests performed and 
higher test result yields compared with another SA hospital of similar 
size. Against the background of increasing trends in IFE testing at our 
hospital, the proportion of negative IFE test results, particularly for 
UIFE, emphasises the value of clinical evaluation when interpreting 
electrophoresis results.
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